{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-003470","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2024-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.958067+00:00","generated_at":"2026-06-06T23:55:42.284526+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Avenue Therapeutics shareholders approve increase in authorized shares from 75M to 200M and warrant issuance","bullets":["Written consent from holders of 56.4% voting power approved Authorized Share Increase to 200M shares.","Issuance of warrants (Jan 5 inducement) exceeding 20% of outstanding common stock authorized.","Authorized common stock increased from 75M to 200M shares via amendment to certificate of incorporation.","Board also approved the share increase, share issuance, and amendment."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-003470","json":"https://secwatch.observer/filing/0001104659-24-003470.json","markdown":"https://secwatch.observer/filing/0001104659-24-003470.md","text":"https://secwatch.observer/filing/0001104659-24-003470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000110465924003470/0001104659-24-003470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000110465924003470/tm243128d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T23:55:42.284526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7a1856acbb4c5728f044510fb7deb36d9171761b","claim":"AVENUE THERAPEUTICS, INC. shareholders approved Authorization of the issuance of shares of Common Stock underlying warrants in an amount equal to or in excess of 20% of outstanding Common Stock at the 2024-01-09 meeting.","evidence_excerpt":"Effective January 9, 2024, the holders of a majority of the voting power of the capital stock of Avenue Therapeutics, Inc. (the “ Company ”) executed a written consent (i) approving an increase in the number of the Company’s authorized shares of common stock, par value $0.0001 per share (“ Common Stock ”), from 75,000,000 to 200,000,000 (the “ Authorized Share Increase ”) through the filing of an amendment (the “ Amendment ”) to the Company’s Third Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware and (ii) authorizing, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of Common Stock underlying warrants issued by the Company pursuant to those previously disclosed inducement letter agreements, dated as of January 5, 2024, by and between the Company and the investors named on the signature pages thereto, in an amount equal to or in excess of 20% of the number of shares of Common Stock outstanding immedi","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465924003470/0001104659-24-003470-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-01-09"}],"fact_type":"shareholder_vote"},{"claim_id":"d8cd14efc33488a3a744fe2934137dab5f94d719","claim":"AVENUE THERAPEUTICS, INC. shareholders approved Approval of an increase in the number of authorized shares of Common Stock from 75,000,000 to 200,000,000 at the 2024-01-09 meeting.","evidence_excerpt":"Effective January 9, 2024, the holders of a majority of the voting power of the capital stock of Avenue Therapeutics, Inc. (the “ Company ”) executed a written consent (i) approving an increase in the number of the Company’s authorized shares of common stock, par value $0.0001 per share (“ Common Stock ”), from 75,000,000 to 200,000,000 (the “ Authorized Share Increase ”) through the filing of an amendment (the “ Amendment ”) to the Company’s Third Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware and (ii) authorizing, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of Common Stock underlying warrants issued by the Company pursuant to those previously disclosed inducement letter agreements, dated as of January 5, 2024, by and between the Company and the investors named on the signature pages thereto, in an amount equal to or in excess of 20% of the number of shares of Common Stock outstanding immedi","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465924003470/0001104659-24-003470-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-01-09"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}